1253186-49-0 Usage
Description
GSK-5498A is a chemical compound that belongs to a class of phosphodiesterase 4 (PDE4) inhibitors, which are being investigated for their potential anti-inflammatory and immunomodulatory effects. PDE4 inhibitors work by preventing the breakdown of cyclic adenosine monophosphate (cAMP) within cells, leading to increased cAMP levels and subsequent modulation of inflammatory responses. GSK-5498A has shown promising activity in preclinical studies, suggesting potential applications in the treatment of a variety of inflammatory diseases.
Used in Pharmaceutical Industry:
GSK-5498A is used as an anti-inflammatory and immunomodulatory agent for its potential to treat a variety of inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and psoriasis. Its mechanism of action involves the inhibition of PDE4, which prevents the breakdown of cAMP, leading to increased cAMP levels and modulation of inflammatory responses.
Clinical trials and further research are ongoing to evaluate the safety and efficacy of GSK-5498A as a potential therapeutic agent for these conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1253186-49-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,3,1,8 and 6 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1253186-49:
(9*1)+(8*2)+(7*5)+(6*3)+(5*1)+(4*8)+(3*6)+(2*4)+(1*9)=150
150 % 10 = 0
So 1253186-49-0 is a valid CAS Registry Number.
1253186-49-0Relevant articles and documents
Optical Control of CRAC Channels Using Photoswitchable Azopyrazoles
Yang, Xingye,Ma, Guolin,Zheng, Sisi,Qin, Xiaojun,Li, Xiang,Du, Lupei,Wang, Youjun,Zhou, Yubin,Li, Minyong
supporting information, p. 9460 - 9470 (2020/06/27)
The Ca2+ release-activated Ca2+ (CRAC) channels control many Ca2+-modulated physiological processes in mammals. Hyperactivating CRAC channels are known to cause several human diseases, including Stormorken syndrome. Here, we show the design of azopyrazole-derived photoswitchable CRAC channel inhibitors (designated piCRACs), which enable optical inhibition of store-operated Ca2+ influx and downstream signaling. Moreover, piCRAC-1 has been applied in vivo to alleviate thrombocytopenia and hemorrhage in a zebrafish model of Stormorken syndrome in a light-dependent manner.
